Our Products

Clinical Trials

Angiocept (CT-322): Phase 1 in United States

Our first Adnectin™ product, Angiocept™ (CT-322), is currently in Phase I clinical development in oncology in the United States. The trial is an open label, multi-dose, dose escalation study designed to evaluate safety and tolerability.

To learn more about this trial, please go to the following internet link:
http://www.clinicaltrials.gov/ct/show/NCT00374179?order=1Angiocept

Angiocept (CT-322): Phase 2

We have initiated a multicenter Phase 2 clinical study of Angiocept (CT-322) in patients with recurrent glioblastoma multiforme (GBM), the most common and aggressive type of primary brain tumor. To learn more about this trial, which is known as PARADIGM (Phase 2 Assessment of a VEGFR-2 Adnectin In Glioblastoma Multiforme), please click on: http://www.clinicaltrial.gov/ct2/show/NCT00562419&term=CT322&rank=1

To learn more about Angiocept go to: Our Pipeline